Pfizer Inc. (PFE) filed a Form 8K - Changes in Company Executive Management - with the U.S Securities and Exchange Commission on February 23, 2017.

 

On February 23, 2017, the Board of Directors of Pfizer Inc. (the "Company") elected Ronald E. Blaylock to serve as a member of the Company's Board of Directors, effective immediately. In addition, he was elected to the Corporate Governance Committee and the Science and Technology Committee of the Board.

Mr. Blaylock has been provided an indemnification agreement and will receive compensation in accordance with the Company's standard arrangements for non-employee directors. The press release, dated February 23, 2017, announcing the election of Mr. Blaylock is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000007800317000015/nx8k223.htm

 

Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/78003/000007800317000015/0000078003-17-000015-index.htm

 

Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.

 
 

(END) Dow Jones Newswires

February 23, 2017 17:20 ET (22:20 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Pfizer Charts.